Fluor Sells AMECO South America to STRACON Group
Get Alerts FLR Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.3%
EPS Growth %: +62.8%
Join SI Premium – FREE
Transaction marks completion of AMECO divestiture
IRVING, Texas--(BUSINESS WIRE)-- Fluor Corporation (NYSE: FLR) announced today that the company sold its AMECO South America business, which includes assets in Chile and Peru, to STRACON Group, a diversified strategic partner to the mining sector in the Americas.
This transaction marks the completion of the AMECO divestiture which was a strategic initiative to allow Fluor to focus on its core businesses and capital priorities. Previous AMECO divestitures included company assets in Africa, the Caribbean, Mexico and North America.
AMECO South America is a provider of integrated mobile equipment services, solutions and rentals that serves ongoing operations and capital projects in the mining industry.
About Fluor Corporation
Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 40,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $13.7 billion in 2022 and is ranked 259 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005847/en/
Brett Turner
Media Relations
864.281.6976
Jason Landkamer
Investor Relations
469.398.7222
Source: Fluor Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fluor Divests Equity Stake in Mexico JV
- Danske Bank A/S revises 2026 net profit outlook upwards. Now expects a net profit in the range of DKK 23-25 billion
- Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share